TGFBR1 and neoplasm: EGFR inhibitors, including cetuximab and lapatinab, can dramatically reduce tumor burden in HNSCC animal models [26] or patients [11] In the present study, the EGFR pathway is frequently activated in Tgfbr1/Pten 2cKO mice.